# GLPG0259 Multiple Ascending Dose and Methotrexate Drug-drug Interaction (DDI) in Healthy Subjects

> **NCT00989703** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** placebo
- **DRUG:** GLPG0259
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT00989703
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2009-11
- **Final completion:** 2010-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2012-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00989703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00989703, "GLPG0259 Multiple Ascending Dose and Methotrexate Drug-drug Interaction (DDI) in Healthy Subjects". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00989703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*